Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Assets (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Assets data on record, last reported at $842.8 million in Q4 2025.

  • For Q4 2025, Assets rose 25.65% year-over-year to $842.8 million; the TTM value through Dec 2025 reached $842.8 million, up 25.65%, while the annual FY2025 figure was $842.8 million, 25.65% up from the prior year.
  • Assets reached $842.8 million in Q4 2025 per MIRM's latest filing, up from $785.1 million in the prior quarter.
  • Across five years, Assets topped out at $842.8 million in Q4 2025 and bottomed at $222.2 million in Q1 2021.
  • Average Assets over 5 years is $503.1 million, with a median of $545.1 million recorded in 2023.
  • The widest YoY moves for Assets: up 95.47% in 2024, down 2.65% in 2024.
  • A 5-year view of Assets shows it stood at $294.7 million in 2021, then rose by 19.77% to $352.9 million in 2022, then soared by 83.23% to $646.6 million in 2023, then increased by 3.73% to $670.8 million in 2024, then increased by 25.65% to $842.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $842.8 million in Q4 2025, $785.1 million in Q3 2025, and $725.8 million in Q2 2025.